Loading organizations...
§ Private Profile · San Francisco, CA, USA
SmithRx is a technology company.
SmithRx has raised $99.0M across 4 funding rounds.
Key people at SmithRx.
SmithRx has raised $99.0M in total across 4 funding rounds.
SmithRx operates as a modern pharmacy benefits manager, applying technology to ensure transparency and efficiency in prescription drug pricing. The company uses a 100% pass-through model, removing opaque fees. With data analytics and a broad network of independent pharmacies, SmithRx aims to improve access to affordable medications and optimize client pharmacy spend.
Founder Jake Frenz established SmithRx, driven by profound personal and family healthcare experiences. His journey through severe illnesses revealed significant inefficiencies and a lack of transparency in prescription medication management. This insight fueled his mission to build a pharmacy benefits model centered on fairness and clarity.
SmithRx primarily serves employers and patients, working to secure the lowest possible prescription drug costs. Its mission upholds transparency and integrity across the pharmacy benefits landscape. SmithRx envisions transforming this critical healthcare segment, striving for greater equity, efficiency, and accessibility in medication management.
SmithRx is a San Francisco-based technology company founded in 2016 that operates as a modern Pharmacy Benefits Manager (PBM), delivering prescription drug benefits through a radically transparent, 100% pass-through pricing model.[1][2][3][5][7] It serves employers, organizations, and members by providing the lowest-cost medication pathways via cutting-edge technology, including custom portals, mobile access, and programs like Connect 360 for autoimmune treatments, achieving average pharmacy cost reductions of 30% and up to 95% savings on high-cost drugs with $0 copays.[1][3][4][6][7] This solves core problems in the opaque U.S. PBM industry—hidden fees, rebate retention, and complexity—through auditable pricing, all manufacturer rebates passed directly to clients, and white-glove service on a single, reliable platform.[2][3][5]
SmithRx was founded in 2016 by Jake Frenz, driven by his personal healthcare struggles: caring for his father with cancer at age 22, facing his own cancer diagnosis that risked leg amputation, and later managing specialty drugs for his ill mother.[5] These experiences exposed systemic U.S. healthcare failures like opacity and unfair pricing in pharmacy benefits, inspiring Frenz to launch a transparent PBM alternative prioritizing employers' and patients' interests.[2][5][7] Early traction came from building a state-of-the-art platform with pass-through rebates, drug cost guarantees, and concierge service; by implementing HIPAA-compliant Salesforce tools in under 10 weeks, SmithRx gained reliable sales forecasting, pipeline visibility, and 100% team adoption without disruption.[2]
SmithRx rides the wave of PBM modernization, targeting a $500B+ U.S. pharmacy benefits market plagued by opacity, where traditional players retain rebates and inflate costs amid rising drug prices and biosimilar adoption.[1][3][5][7] Timing aligns with post-2020 scrutiny on healthcare transparency (e.g., via laws like the Inflation Reduction Act) and tech-driven disruption in fintech-adjacent healthtech, enabling smaller, agile PBMs to capture share from incumbents.[7] Favorable forces include biosimilar launches reducing specialty drug costs and employer demands for cost control; SmithRx influences the ecosystem by pioneering tech-enabled equity, inspiring competitors, and proving scalable savings for mid-market employers.[1][2][6][7]
SmithRx is poised for accelerated growth through biosimilar expansions, AI-enhanced pathways, and potential enterprise scaling, building on 2024-2025 momentum like 30% cost cuts and $14.5M savings pilots.[1][6][7] Trends like value-based care, regulatory rebate reforms, and healthtech consolidation will amplify its transparent model, potentially positioning it for IPO or acquisition as pre-IPO interest grows.[7] Its influence may evolve from niche disruptor to category leader, redefining PBMs around technology and trust—echoing its founding mission to humanize pharmacy benefits for all.[5]
SmithRx has raised $99.0M in total across 4 funding rounds.
SmithRx's investors include Venrock, First Round Capital, F-Prime Capital Partners, Moderne Ventures, Jonathan Bush, Kevin Nazemi, Daffy, Footprint Coalition, Pareto Holdings, Presight Capital, rocketship.vc, Shaan's All Access Fund.
SmithRx has raised $99.0M across 4 funding rounds. Most recently, it raised $60.0M Series C in January 2024.
Key people at SmithRx.
